Sarepta stock hit by renewed uncertainty about gene therapy treatment for rare disease
April 13, 2023 at 13:24 PM EDT
A report said the FDA was leaning toward rejecting a treatment for Duchenne muscular dystrophy that the company seemed to view as a sure thing.
